Goldman Sachs
CMPI

Goldman Sachs’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Goldman Sachs’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,600
Closed -$145K – 5814
2020
Q3 		$145K Buy
+12,600
New +$162K ﹤0.01% 5010

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs's CMPI Position: Q4 2020 in Review

Goldman Sachs sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q4 2020, closing a stake of 12,600 shares — an estimated $145K sold.

Goldman Sachs first reported a position in CMPI in Q3 2020 and held it in 1 quarter. The position peaked at $145K in Q3 2020. 36 funds tracked by Wall St. Rank hold CMPI as of Q4 2020.

  • Goldman Sachs reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Goldman Sachs sold 12,600 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $145K.
  • Goldman Sachs first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Goldman Sachs's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $145K in Q3 2020.
  • 36 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.